| Dimensions Living Burr Ridge | |
| 6801 Highgrove Boulevard, Burr Ridge, Illinois 60521 | |
| (630) 920-2900 | |
| Name | Dimensions Living Burr Ridge |
|---|---|
| Location | 6801 Highgrove Boulevard, Burr Ridge, Illinois |
| Certified By | Medicare |
| No. of Certified Beds | 29 |
| Occupancy Rate | 51.03% |
| Medicare ID (CCN) | 146094 |
| Legal Business Name | Sh Opco Burr Ridge Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1427372960 |
| Organization Name | EMERICARE INC |
| Doing Business As | EMERITUS AT BURR RIDGE |
| Address | 6801 High Grove Blvd, Burr Ridge, IL 60527 |
| Phone Number | 630-920-2900 |
News Archive
Sosei Group Corporation announce the commencement of the Phase III clinical programme by Novartis, with QVA149, a once-daily, dry powder bronchodilator for inhalation combining a fixed dose of the once-daily beta2-agonist QAB149 (indacaterol) and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide) for the treatment of chronic obstructive pulmonary disease (COPD). The start of Phase III triggers a $7.5m milestone payment to Sosei.
The largest and most comprehensive mental health survey of college students in the US reveals that students who identify as transgender, gender nonconforming, genderqueer, and nonbinary face enormous mental health disparities relative to their peers.
Long-term use of antiepileptic drugs is a significant risk factor for vitamin D deficiency in children with epilepsy.
Researchers from Russian Academy of Sciences developed a new method for star-shaped nanoparticles synthesis based on laser irradiation.
› Verified 7 days ago
| NPI Number | 1447669353 |
| Organization Name | S-H OPCO BURR RIDGE, LLC |
| Doing Business As | DIMENSIONS LIVING BURR RIDGE |
| Address | 6801 High Grove Blvd, Burr Ridge, IL 60527 |
| Phone Number | 630-920-2900 |
News Archive
Sosei Group Corporation announce the commencement of the Phase III clinical programme by Novartis, with QVA149, a once-daily, dry powder bronchodilator for inhalation combining a fixed dose of the once-daily beta2-agonist QAB149 (indacaterol) and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide) for the treatment of chronic obstructive pulmonary disease (COPD). The start of Phase III triggers a $7.5m milestone payment to Sosei.
The largest and most comprehensive mental health survey of college students in the US reveals that students who identify as transgender, gender nonconforming, genderqueer, and nonbinary face enormous mental health disparities relative to their peers.
Long-term use of antiepileptic drugs is a significant risk factor for vitamin D deficiency in children with epilepsy.
Researchers from Russian Academy of Sciences developed a new method for star-shaped nanoparticles synthesis based on laser irradiation.
› Verified 7 days ago
| NPI Number | 1588617419 |
| Organization Name | PRIME CARE SEVEN, LLC |
| Address | 6801 High Grove Blvd, Burr Ridge, IL 60527 |
| Phone Number | 630-920-2900 |
News Archive
Sosei Group Corporation announce the commencement of the Phase III clinical programme by Novartis, with QVA149, a once-daily, dry powder bronchodilator for inhalation combining a fixed dose of the once-daily beta2-agonist QAB149 (indacaterol) and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide) for the treatment of chronic obstructive pulmonary disease (COPD). The start of Phase III triggers a $7.5m milestone payment to Sosei.
The largest and most comprehensive mental health survey of college students in the US reveals that students who identify as transgender, gender nonconforming, genderqueer, and nonbinary face enormous mental health disparities relative to their peers.
Long-term use of antiepileptic drugs is a significant risk factor for vitamin D deficiency in children with epilepsy.
Researchers from Russian Academy of Sciences developed a new method for star-shaped nanoparticles synthesis based on laser irradiation.
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Sosei Group Corporation announce the commencement of the Phase III clinical programme by Novartis, with QVA149, a once-daily, dry powder bronchodilator for inhalation combining a fixed dose of the once-daily beta2-agonist QAB149 (indacaterol) and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide) for the treatment of chronic obstructive pulmonary disease (COPD). The start of Phase III triggers a $7.5m milestone payment to Sosei.
The largest and most comprehensive mental health survey of college students in the US reveals that students who identify as transgender, gender nonconforming, genderqueer, and nonbinary face enormous mental health disparities relative to their peers.
Long-term use of antiepileptic drugs is a significant risk factor for vitamin D deficiency in children with epilepsy.
Researchers from Russian Academy of Sciences developed a new method for star-shaped nanoparticles synthesis based on laser irradiation.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 3.12 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 21.88 | 5.51 |